Events

Seminar: Export control in a geopolitical context
MAR
Tue
18
08:30 - 00:00

This was 8 months ago

Location

Brussels

Bd Simon Bolivar 17, 1000.
Programmes
Security Cybersecurity Defence

Attachments

There is 1 attachment connected to this article.

Attachments are only accessible for people with an account on the NCP Flanders website.

Sign in (if you already have an account) or sign up.

The Flemish Department of Foreign Affairs - Strategic Goods Control Unit (dienst Controle Strategische Goederen) invites you to its annual event, which this year will focus on “Export Control in a Geopolitical Context.”

The seminar will explore the impact of and interactions with a European economic security strategy, as well as the growing opportunities in defence programs and funding.

Attendees will have the opportunity to meet the team, ask questions, and network.

The full agenda of this event can be found in the attached document.

To register for this event, please access this link

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.